Thử nghiệm cho thấy 3 PROOF RẰNG telaprevir dựa trên ba điều trị cũng được cải thiện đáng kể tỷ lệ SVR trong kiểu gen HCV 1 relapsers (69-76%) và không đáp ứng (38-39%) so với retreatment với tiêu chuẩn chăm sóc (14%) (McHutchison 2010). | 5. New Agents for Treating Hepatitis C 53 The PROVE 3 trial showed that telaprevir-based triple therapy also greatly improved SVR rates in HCV genotype 1 relapsers 69-76 and non-responders 38-39 compared to retreatment with standard of care 14 McHutchison 2010 . As in the PROVE 1 and 2 studies viral breakthrough was observed more frequently in patients infected with genotype 1a than in patients infected with genotype 1b. Nevertheless the results of PROVE 3 indicate that STAT-C compounds have an enormous potency in prior non-responders and relapsers to standard treatment. Telaprevir and different HCV genotypes. Telaprevir alone or in combination with PEG-IFN and ribavirin was less effective in treatment-naive patients infected with other genotypes. For HCV genotype 2 a somewhat weaker antiviral activity in comparison with genotype 1 with a mean viral decline of log10 lU ml over 14 days monotherapy was observed in genotype 3 and 4 patients no significant antiviral activity was detectable log10 decline Benhamou 2010 Foster 2010 . Telaprevir phase III studies. The ADVANCE trial enrolled more than 1000 treatment-naive HCV genotype 1 patients to evaluate 24 and 48 weeks of telaprevir-based therapy Jacobson 2010 . Tel-aprevir was dosed at 750 mg every 8 hours and given for 8 or 12 weeks in combination with PEG-IFN a-2a and ribavirin followed by PEG-IFN a-2a and ribavirin alone until treatment week 24 or 48. A response-guided approach was applied to define the overall treatment period. Patients with or without an extended rapid virologic response eRVR undetectable HCV RNA at treatment weeks 4 and 12 received 24 or 48 weeks of total therapy respectively. The novel concept of eRVR was introduced in order to identify patients with viral breakthrough of telaprevir resistant variants which may occur after achieving RVR according to the traditional definition. SVR rates in the ADVANCE trial were 69 and 75 for 8 and 12 weeks triple the Tphjsi bj sortrial to ersi nse .
